TipRanks
Advertisement
Advertisement

ZYME Stock Latest News

Roche Collaboration and Royalty-Focused Model Drive Higher Zymeworks Valuation, Supporting Buy Rating
RatingsRoche Collaboration and Royalty-Focused Model Drive Higher Zymeworks Valuation, Supporting Buy Rating
14h ago
ZYME
Zymeworks price target raised to $52 from $50 at Jefferies
PremiumThe Fly
Zymeworks price target raised to $52 from $50 at Jefferies
14h ago
CHRO
ZYME
Zymeworks Announces Global DLL3 T-Cell Engager Partnership
PremiumCompany Announcements
Zymeworks Announces Global DLL3 T-Cell Engager Partnership
22h ago
8K
ZYME
Zymeworks signs collaboration and license agreement with Roche for ZW209
PremiumThe Fly
Zymeworks signs collaboration and license agreement with Roche for ZW209
22h ago
CHRO
ZYME
Zymeworks Sets Q3 2026 Results Date and Ramps Up Investor Conference Presence
PremiumCompany Announcements
Zymeworks Sets Q3 2026 Results Date and Ramps Up Investor Conference Presence
9d ago
ZYME
Zymeworks price target raised to $34 from $32 at Truist
PremiumThe FlyZymeworks price target raised to $34 from $32 at Truist
17d ago
ZYME
Zymeworks reinstated with a Buy at TD Cowen
Premium
The Fly
Zymeworks reinstated with a Buy at TD Cowen
25d ago
ZYME
Zymeworks price target raised to $39 from $38 at Citi
Premium
The Fly
Zymeworks price target raised to $39 from $38 at Citi
25d ago
ZYME
LifeSci flags Yupelri as a key growth driver after Zymeworks’ Theravance deal
PremiumThe Fly
LifeSci flags Yupelri as a key growth driver after Zymeworks’ Theravance deal
26d ago
ZYME
Charles Zhu Reiterates Buy on Zymeworks, Keeps $34 Price Target After TBPH Acquisition Boosts Growth and Cash Flow Outlook
PremiumRatings
Charles Zhu Reiterates Buy on Zymeworks, Keeps $34 Price Target After TBPH Acquisition Boosts Growth and Cash Flow Outlook
26d ago
ZYME
Midday Fly By: Nvidia boosts buyback, Boeing discovers 737 Max glitch
PremiumThe Fly
Midday Fly By: Nvidia boosts buyback, Boeing discovers 737 Max glitch
26d ago
BA
NU
Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M
PremiumThe Fly
Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M
26d ago
ZYME
Zymeworks announces financial impact of Theravance Biopharma acquisition
PremiumThe FlyZymeworks announces financial impact of Theravance Biopharma acquisition
26d ago
ZYME
Zymeworks Closes Theravance Acquisition and CVR Financing
Premium
Company Announcements
Zymeworks Closes Theravance Acquisition and CVR Financing
1M ago
8K
ZYME
Zymeworks initiated with an Outperform at Wolfe Research
Premium
The Fly
Zymeworks initiated with an Outperform at Wolfe Research
1M ago
ZYME
Zymeworks price target raised to $33 from $31 at JPMorgan
PremiumThe Fly
Zymeworks price target raised to $33 from $31 at JPMorgan
2M ago
ZYME
Zymeworks price target raised to $38 from $37 at Citi
PremiumThe Fly
Zymeworks price target raised to $38 from $37 at Citi
2M ago
ZYME
Zymeworks price target raised to $55 from $51 at H.C. Wainwright
PremiumThe Fly
Zymeworks price target raised to $55 from $51 at H.C. Wainwright
2M ago
ZYME
Zymeworks Gains $250 Million Milestone as Jazz Wins FDA Nod for HER2 Cancer Regimens
PremiumCompany Announcements
Zymeworks Gains $250 Million Milestone as Jazz Wins FDA Nod for HER2 Cancer Regimens
2M ago
ZYME
Zymeworks Gains Second FDA Nod for Zanidatamab, Unlocking Major Milestones
PremiumCompany AnnouncementsZymeworks Gains Second FDA Nod for Zanidatamab, Unlocking Major Milestones
2M ago
ZYME
BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA
Premium
The Fly
BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA
2M ago
ONC
JAZZ
Zymeworks says partner Jazz receives FDA approval for Ziihera regimens
Premium
The Fly
Zymeworks says partner Jazz receives FDA approval for Ziihera regimens
2M ago
ONC
JAZZ

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >